BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

October 29, 2018

Study Completion Date

February 11, 2019

Conditions

Endometriosis

Interventions

DRUG

BAY2328065

Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets

DRUG

Placebo

Matching placebo, once daily in an escalating manner as LSF or tablets

Trial Locations (1)

CRS Clinical Research Services Berlin GmbH, Berlin